Dehydroepiandrosterone
From DrugPedia: A Wikipedia for Drug discovery
| Line 27: | Line 27: | ||
|Li J, Vrielink A, Brick P, Blow DMCrystal structure of cholesterol oxidase complexed with a steroid substrate: implications for flavin adenine dinucleotide dependent alcohol oxidasesBiochemistry v32, p.11507-11515 | |Li J, Vrielink A, Brick P, Blow DMCrystal structure of cholesterol oxidase complexed with a steroid substrate: implications for flavin adenine dinucleotide dependent alcohol oxidasesBiochemistry v32, p.11507-11515 | ||
|- | |- | ||
| + | |} | ||
Physical Property Value Units Temp (deg C) Source | Physical Property Value Units Temp (deg C) Source | ||
|Melting Point | |Melting Point | ||
Revision as of 05:05, 31 October 2008
Dehydroepiandrosterone
Pubchem(5881)
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
Negative modulator of GABAA receptors.
Drug Type: Small Molecule; Experimental
KEGG Pathway(C01227) Androgen and estrogen metabolism Prostate cancer
| MMDB ID | PDB ID | Reference |
|---|---|---|
| 15983 | 1E3R | Ha NC, Kim MS, Lee W, Choi KY, Oh BHDetection of large pKa perturbations of an inhibitor and a catalytic group at an enzyme active site, a mechanistic basis for catalytic power of many enzymesJ. Biol. Chem. v275, p.41100-41106 |
| 55806 | 1COY | Li J, Vrielink A, Brick P, Blow DMCrystal structure of cholesterol oxidase complexed with a steroid substrate: implications for flavin adenine dinucleotide dependent alcohol oxidasesBiochemistry v32, p.11507-11515 |
Physical Property Value Units Temp (deg C) Source |Melting Point |140-141 |deg C | |EXP |- |log P (octanol-water) |3.23 |(none) | |EXP |- |Water Solubility |63.5 |mg/L |25 |EXP |- |Vapor Pressure |2.23E-08 |mm Hg |25 |EST |- |Henry's Law Constant |6.62E-09 |atm-m3/mole |25 |EST |- |Atmospheric OH Rate Constant |1.27E-10 |cm3/molecule-sec |25 |EST |- |}
Organism Test Type Route Reported Dose (Normalized Dose) Effect Source |man |TDLo |oral |10mg/kg/2W-I (10mg/kg) |CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) |Annals of Internal Medicine. Vol. 129, Pg. 588, 1998. |- |mouse |LD50 |oral |> 10gm/kg (10000mg/kg) | |British UK Patent Application. Vol. #2208473, |- |mouse |LD50 |subcutaneous |900mg/kg (900mg/kg) |British UK Patent Application. Vol. #2208473, |- |rat |LD50 |oral |> 10gm/kg (10000mg/kg) |British UK Patent Application. Vol. #2208473, |- |rat |LD50 |subcutaneous |1gm/kg (1000mg/kg) |British UK Patent Ap |- |}
